We are live on ! Find out more
RP

Regeneron Pharmaceuticals Portfolio holdings

AUM $177M
1-Year Est. Return 9.82%
This Fund
S&P 500
This Quarter Est. Return
-15.69%
1 Year Est. Return
+9.82%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.09B
AUM Growth
–
Cap. Flow
+$1.23B
Cap. Flow %
112.76%
Top 10 Hldgs %
100%
Holding
6
New
6
Increased
–
Reduced
–
Closed
–
Avg Time Held
0 quarters
Top 10 Avg Time Held
0 quarters
Top 20 Avg Time Held
0 quarters

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$1.17B
2
NTLA icon
Intellia Therapeutics
NTLA
+$57.8M
3
TSVT icon
2seventy bio
TSVT
+$5.15M
4
ADVM icon
Adverum Biotechnologies
ADVM
+$1.22M
5
ACET icon
Adicet Bio
ACET
+$1.14M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ALNY icon
1
Alnylam Pharmaceuticals
ALNY
$29.9B
$1.05B 95.54%
+4,444,445
New +$1.17B
2024 Q4
0 quarters
NTLA icon
2
Intellia Therapeutics
NTLA
$1.67B
$43.2M 3.94%
+3,702,995
New +$57.8M
2024 Q4
0 quarters
TSVT icon
3
DELISTED
2seventy bio
TSVT
$3.69M 0.34%
+1,254,827
New +$5.15M
2024 Q4
0 quarters
ACET icon
4
Adicet Bio
ACET
$47.8M
$931K 0.09%
+60,511
New +$1.14M
2024 Q4
0 quarters
ADVM icon
5
DELISTED
Adverum Biotechnologies
ADVM
$845K 0.08%
+180,909
New +$1.22M
2024 Q4
0 quarters
BLUE icon
6
DELISTED
bluebird bio
BLUE
$175K 0.02%
+21,000
New +$184K
2024 Q4
0 quarters

Similar funds

SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
MSA
Marathon Strategic Advisors Pittsburgh, Pennsylvania $177M AUM 66.85% 1-Year Est. Return
HF
Holcombe Financial Atlanta, Georgia $177M AUM 13.35% 1-Year Est. Return
CWP
Clark Wealth Partners O'fallon, Illinois $177M AUM 22.36% 1-Year Est. Return
BFAG
Blackston Financial Advisory Group The Villages, Florida $177M AUM 21.44% 1-Year Est. Return
WFG
Wormser Freres Gestion Paris, France $177M AUM 13.84% 1-Year Est. Return
AAS
AdviceOne Advisory Services Glastonbury, Connecticut $177M AUM 26.65% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

Regeneron Pharmaceuticals's Q4 2024 Portfolio in Review

Q4 2024 is the first quarter with a 13F filing on record for Regeneron Pharmaceuticals, which disclosed 6 positions worth $1.09B. Its ten largest holdings account for 100% of the portfolio.

Its largest position is Alnylam Pharmaceuticals: 4,444,445 shares worth $1.05B.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets.

  • Regeneron Pharmaceuticals's largest Q4 2024 buy was Alnylam Pharmaceuticals: 4,444,445 shares worth $1.05B.
  • Regeneron Pharmaceuticals's ten largest holdings make up 100% of its $1.09B portfolio in Q4 2024.
  • Regeneron Pharmaceuticals disclosed 6 positions in Q4 2024, its first 13F filing on record.

Based on Regeneron Pharmaceuticals's 13F filing for Q4 2024, filed 7 Feb 2025.